Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of acyclovir therapy on ventilated patients with HSV-1 in BAL
2023-504322-19-00Phase 3Authorised
- Sponsor
- Friedrich Schiller University Jena
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of aciclovir in pneumonia and Herpes simplex virus 1 lower respiratory tract infection (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: 30-day mortality. Planned start Sep 2023; status: authorised.
02
Drugs
aciclovir
03
Conditions
pneumoniaHerpes simplex virus 1 lower respiratory tract infection
Beyond the preview
Go deeper on 2023-504322-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504322-19-00.